These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 22572078)
1. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer. Zhang X; Liu H; Balter P; Allen PK; Komaki R; Pan T; Chuang HH; Chang JY Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1558-65. PubMed ID: 22572078 [TBL] [Abstract][Full Text] [Related]
2. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359 [TBL] [Abstract][Full Text] [Related]
3. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Henderson MA; Hoopes DJ; Fletcher JW; Lin PF; Tann M; Yiannoutsos CT; Williams MD; Fakiris AJ; McGarry RC; Timmerman RD Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):789-95. PubMed ID: 19473777 [TBL] [Abstract][Full Text] [Related]
4. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control. Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800 [TBL] [Abstract][Full Text] [Related]
5. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Hoopes DJ; Tann M; Fletcher JW; Forquer JA; Lin PF; Lo SS; Timmerman RD; McGarry RC Lung Cancer; 2007 May; 56(2):229-34. PubMed ID: 17353064 [TBL] [Abstract][Full Text] [Related]
6. The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). Takeda A; Yokosuka N; Ohashi T; Kunieda E; Fujii H; Aoki Y; Sanuki N; Koike N; Ozawa Y Radiother Oncol; 2011 Nov; 101(2):291-7. PubMed ID: 21889224 [TBL] [Abstract][Full Text] [Related]
7. Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. Horne ZD; Clump DA; Vargo JA; Shah S; Beriwal S; Burton SA; Quinn AE; Schuchert MJ; Landreneau RJ; Christie NA; Luketich JD; Heron DE Radiat Oncol; 2014 Jan; 9():41. PubMed ID: 24479954 [TBL] [Abstract][Full Text] [Related]
8. Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer. Dunlap NE; Yang W; McIntosh A; Sheng K; Benedict SH; Read PW; Larner JM Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1071-7. PubMed ID: 22898383 [TBL] [Abstract][Full Text] [Related]
9. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy. Tanaka H; Hayashi S; Hoshi H Asia Pac J Clin Oncol; 2016 Mar; 12(1):e113-7. PubMed ID: 24176011 [TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome? Clarke K; Taremi M; Dahele M; Freeman M; Fung S; Franks K; Bezjak A; Brade A; Cho J; Hope A; Sun A Radiother Oncol; 2012 Jul; 104(1):62-6. PubMed ID: 22682749 [TBL] [Abstract][Full Text] [Related]
12. Using max standardized uptake value from positron emission tomography to assess tumor responses after lung stereotactic body radiotherapy for different prescriptions. Ding M; Zollinger W; Ebeling R; Heard D; Posey R J Appl Clin Med Phys; 2018 Nov; 19(6):226-233. PubMed ID: 30216639 [TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. Taremi M; Hope A; Dahele M; Pearson S; Fung S; Purdie T; Brade A; Cho J; Sun A; Bissonnette JP; Bezjak A Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):967-73. PubMed ID: 21377293 [TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer. Ebright MI; Russo GA; Gupta A; Subramaniam RM; Fernando HC; Kachnic LA J Thorac Cardiovasc Surg; 2013 Mar; 145(3):709-15. PubMed ID: 23317944 [TBL] [Abstract][Full Text] [Related]
15. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222 [TBL] [Abstract][Full Text] [Related]
16. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy. Pyka T; Bundschuh RA; Andratschke N; Mayer B; Specht HM; Papp L; Zsótér N; Essler M Radiat Oncol; 2015 Apr; 10():100. PubMed ID: 25900186 [TBL] [Abstract][Full Text] [Related]
17. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value. Satoh Y; Onishi H; Nambu A; Araki T Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640 [TBL] [Abstract][Full Text] [Related]
18. Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer. Pastis NJ; Greer TJ; Tanner NT; Wahlquist AE; Gordon LL; Sharma AK; Koch NC; Silvestri GA Chest; 2014 Aug; 146(2):406-411. PubMed ID: 24577678 [TBL] [Abstract][Full Text] [Related]
19. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy. Tan D; Gill S; Loh N Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054 [TBL] [Abstract][Full Text] [Related]
20. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation. Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]